Tag: verteporfin

Modulight Spotlights: LASER-SHARP RESEARCH – November 2025

Laser-sharp Research / cancer, chemotherapy, drug delivery, glioblastoma, in vitro, laser-sharp research, ML8500, multidrug resistance, photoactivated chemotherapy, Photoimmunotherapy, preclinical, therapy resistance, tumor, University of Maryland, verteporfin / November 19, 2025

Modulight Spotlights: LASER-SHARP RESEARCH – November 2025 We are delighted to highlight new exciting study by Rahman et al. from Dr. Huang-Chiao Huang’s lab at University of Maryland. Multidrug resistance remains a significant barrier to successful chemotherapy outcomes for cancer patients, often caused by active pumping of chemotherapeutics outside of cancer cells. Hence, the team [...]

Modulight Spotlights: LASER-SHARP RESEARCH – November 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – April 2025

Laser-sharp Research / drug delivery, imaging, in vitro, laser-sharp research, light activation, ML6600, nanoparticles, Photodynamic therapy, Photoimmunotherapy, verteporfin / April 30, 2025

Gokalp et al. from University of Massachusetts and Tufts University constructed an innovative liquid metal nanoparticle platform, which has tumor cell targeting and enhanced encapsulation of verteporfin. Charactierization in vitro with the help of ML6600 laser showed effective in vitro phototoxicity.

Modulight Spotlights: LASER-SHARP RESEARCH – April 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – February 2025

Laser-sharp Research / breast cancer, cancer, Cancer therapy, cancer treatment, immunology, immunotherapy, in vitro, in vivo, laser-sharp research, ML6600, photosensitizer, research, tumor, verteporfin / February 17, 2025

A. Lepland and the teams at University of Tartu, Estonia and Veneto Institute of Oncology, Italy, developed a new immunotherapy for triple negative breast cancer, using Modulight ML6000-series laser. Tumor growth slowed down and the cancer’s spreading to the lungs was suppressed.

Modulight Spotlights: LASER-SHARP RESEARCH – February 2025 Read More »

Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer

Scientific papers / 689 nm, breast cancer, immunology, immunotherapy, in vitro, in vivo, ML6600, photosensitizer, tumor, verteporfin / January 22, 2025

Published in: Advanced Science Authors: Anni Lepland, Elisa Peranzoni, Uku Haljasorg, Eliana K. Asciutto, Maria Crespí-Amer, Lorenzo Modesti, Kalle Kilk, Manuel Lombardia, Gerardo Acosta, Miriam Royo, Pärt Peterson, Ilaria Marigo, Tambet Teesalu, Pablo Scodeller

Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer Read More »

Self-Assembled Verteporfin Nanoparticles for Photodynamic and Light-Independent Therapy in Glioblastoma

Scientific papers / 690 nm, glioblastoma, in vitro, in vivo, ML6600, PDT, University of Maryland, verteporfin / September 28, 2024

Published in: Advanced NanoBioMed Research Authors: John A. Quinlan, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Robert W. Robey, Michael M. Gottesman, Huang-Chiao Huang

Self-Assembled Verteporfin Nanoparticles for Photodynamic and Light-Independent Therapy in Glioblastoma Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – November 2023

Laser-sharp Research / antibioticresistance, antimicrobial, Cell, drug resistance, in vitro, laser-sharp research, LaserSharpResearch, ML7710, verteporfin / November 14, 2023

Many infectious agents have developed resistance to antibiotics. To combat this problem, Professor Timothy Haystead’s team at Duke University developed a novel light-based antimicrobial strategy that targets non-essential enzyme on the surface of bacteria. Light activation was done using ML7710 with 693 nm laser light to generate reactive oxygen species that successfully sterilized the bacteria.

Modulight Spotlights: LASER-SHARP RESEARCH – November 2023 Read More »

Targeting Borrelia burgdorferi HtpG with a berserker molecule, a strategy for anti-microbial development

Scientific papers / antimicrobial, Borrelia bugdorferi, Cell, drug resistance, enzyme, HtpG, in vitro, ML7710, verteporfin / November 1, 2023

Published in: Cell Chemical Biology Authors: Dave L. Carlson, Mark Kowalewski, Khaldon Bodoor, Matthew R. Redinbo, Neil Spector, Timothy A.J. Haystead Duke University

Targeting Borrelia burgdorferi HtpG with a berserker molecule, a strategy for anti-microbial development Read More »

Light penetration depth in brain with different photosensitizers

Application Note / 5-ALA, 635 nm, 689 nm, BPD, brain cancer, glioblastoma, ML6600, PDT, Photoimmunotherapy, PIT, PPIX, University of Maryland, verteporfin / October 28, 2021

Motivation for the study Glioblastoma is the most aggressive and lethal brain cancer with an average prognosis of 15 months. Fluorescence-guided surgery (FGS) for glioblastoma was FDA-approved in 2017, while photodynamic therapy (PDT) remains an active area of clinical investigation with very promising results so far. The aim of PDT is to eradicate the

Light penetration depth in brain with different photosensitizers Read More »

Development of heat shock protein 90-targeted PDT for inflammatory breast cancer

Application Note / 665 nm, 689 nm, 750 nm, breast cancer, Duke University, HS201, HSP90, in vitro, in vivo, ML7710, ML8500, verteporfin / May 17, 2021

Motivation of the study In photodynamic therapy (PDT), systemically administered photosensitizer is activated within the tumor using focused near-infrared light, typically a laser with a wavelength matching the absorption peak of the photosensitizer. Several photosensitizers have been clinically approved for the treatment of different cancers; however, their accumulation is non-tumor exclusive which exposes healthy tissues

Development of heat shock protein 90-targeted PDT for inflammatory breast cancer Read More »